Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose versus full-dose protamine after coronary artery bypass grafting
IRCT20220610055128N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of protamine in coronary arteriosclerosis (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Activated clotting time, Postoperative bleeding and 1 more. Started Mar 2023; status: completed.
02
Drugs
protamine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20220610055128N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220610055128N1.